Nanobiotix S.A. (NBTX) is the Nasdaq-listed American Depositary Receipt (ADR) of a French, late-stage clinical biotechnology company developing radioenhancers — therapies designed to amplify the effect of radiation against tumors. Its lead asset, NBTXR3 (now JNJ-1900), is being advanced through a global licensing and collaboration agreement with Janssen, the pharmaceutical arm of Johnson & Johnson. This article examines whether the shares can reach a central analyst price target of $53.
This analysis reviewed six individual, verifiable price targets from research coverage of NBTX. Among the more recent figures, Guggenheim initiated coverage with a Buy and a $64 target; H.C. Wainwright raised its target to the equivalent of about $64 (€60) on updated efficacy results; Jefferies lifted its target to a similar level; Stifel stood near $48; Leerink Partners raised its target to $46 from $37 after fourth-quarter results; and one Hold-rated firm carried a $30 target. The simple average of these six targets is roughly $52.70, rounded to a central target of $53, with a low-to-high range of about $30 to $64.
The spread is unusually wide. Bullish analysts emphasize the radioenhancer mechanism and the validation of a large pharmaceutical partner, while more cautious voices point to a still-unprofitable, clinical-stage company whose revenue is episodic and milestone-dependent. No single target should be treated as more likely than another; the average is a midpoint, not a guarantee.
At a last verified close of $31.37 (October 30, 2026), NBTX sits near the lower-middle of its 52-week range of $17.42 to $57.14. Reaching the $53 central target would require a gain of about 69% from that level — a very large move. Notably, the stock has already traded above $53 within the past year, peaking near $57.14, so the target implies a return to prior highs rather than new ground.
The path is fundamentally tied to clinical execution. Nanobiotix reported updated Part 1 efficacy results from the Phase 2 CONVERGE study of JNJ-1900 as a radiotherapy enhancer in stage 3, inoperable non-small cell lung cancer, which drove several target increases in mid-2026. Because revenue remains small and milestone-driven, valuation depends heavily on trial outcomes and the partnership economics with Janssen.
The central pillar is the Johnson & Johnson collaboration, which lends both capital and credibility to the radioenhancer platform. Positive CONVERGE data already triggered a wave of upward target revisions, suggesting analysts are willing to re-rate the shares quickly when clinical news improves. Additional supportive factors include a cash position of roughly $111 million against about $107 million in debt as of the most recent quarter, a mostly Buy-rated analyst base, and a differentiated approach to radiotherapy that could address large oncology indications.
The principal obstacle is that Nanobiotix is not yet profitable: trailing twelve-month revenue was only about $11.5 million, and the company carries a negative book value per share. Cash is nearly matched by debt, so future funding, milestone payments, or financing may be required. Biotech outcomes are binary — disappointing later-stage data, regulatory delays, or a slowdown in the Janssen program could compress the shares sharply. The $30 Hold-rated target illustrates that not all analysts share the bullish view, and the stock's beta and history of wide trading ranges make it prone to sharp drawdowns.
The 52-week high near $57.14 marks the clearest resistance zone, just above the $53 target; a prior high also means the level is a realistic but hard-won hurdle. On the downside, the $30 area — coinciding with the lowest analyst target and recent pre-market trading near $29.50 — serves as a notable support zone. The shares closed below both the 50-day moving average of about $32.53 and the 200-day moving average of about $33.85, indicating the stock needs to reclaim those levels to rebuild upward momentum.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms differ and biotech timelines can stretch well beyond that. Investors should monitor further CONVERGE and head-and-neck data readouts, updates from Janssen on development progress and milestone payments, quarterly cash burn and any financing activity, and analyst target revisions, which have historically moved this stock quickly in both directions.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single static forecast, the system updates its view as conditions change, helping traders spot opportunities, track positions, and identify emerging trends more efficiently. For those seeking an objective, data-driven complement to analyst research on names like NBTX, these signals offer a practical way to stay ahead of changing market structure.
Can Nanobiotix (NBTX) reach $53? The question is analytically meaningful because the central target, a mean of six verified analyst targets ranging from about $30 to $64, sits roughly 69% above the latest close and below the stock's prior 52-week high. Support rests on the Janssen partnership and encouraging CONVERGE data that has already prompted repeated upward revisions. The obstacles are equally real: an unprofitable, milestone-dependent business, a balance sheet where cash is nearly offset by debt, and the inherent binary risk of clinical-stage biotech. With wide analyst disagreement and a recent close beneath its major moving averages, the shares face a substantial climb. Investors should weigh the clinical catalysts and funding dynamics carefully before drawing conclusions — no analyst target, including this average, is a forecast of what will happen.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NBTX has been loosely correlated with FDMT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NBTX jumps, then FDMT could also see price increases.
| Ticker / NAME | Correlation To NBTX | 1D Price Change % | ||
|---|---|---|---|---|
| NBTX | 100% | +2.62% | ||
| FDMT - NBTX | 34% Loosely correlated | -0.16% | ||
| SLDB - NBTX | 34% Loosely correlated | +2.14% | ||
| CLLS - NBTX | 34% Loosely correlated | -0.89% | ||
| ASMB - NBTX | 33% Loosely correlated | -2.02% | ||
| NAMS - NBTX | 33% Poorly correlated | +0.95% | ||
More | ||||